herpes simplex virus thymidine kinase promoter (HSV tk promoter), Jellyfish GFP cDNA, Phage P1 loxP, E. coli neo, mouse CD148 genomic DNA Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol> Fluorescent Proteins/lacZ System 佐竹　正延 Developed by Dr Takamune Takahashi at Vanderbilt University Medical Center in 2003. A targeting construct containing EGFP and neo was transfered into ES cells to disrupt Ptprj gene. GFP fluorescence was not detected in mutant mice. 作製後、 B6/J (日本クレア) に8代バッククロスした。 CD148/DEP-1 KO/PTPRJ CD148/DEP-1 KO/PTPRJ C（3〜6か月） Tohoku Univ. true C (3-6 months) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Mol. Cell. Biol., 23, 1817-1831 (2003).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. The RECIPIENT agrees to include the DEPOSITOR as a co-author in any publications resulted by the use of the BIOLOGICAL RESOURCE during the first 2 years after deposition by the DEPOSITOR to the RIKEN BRC.<br>The RECIPIENT should contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. RBRC01477 Backcross to C57BL/6 (Heterozygote x C57BL/6JJcl) <a href='https://brc.riken.jp/mus/pcr01477'>Genotyping protocol -PCR-</a> CD148/DEP-1 KO/PTPRJ, CD148 KO CD148/DEP-1 KO/PTPRJ, CD148 KO B6.129S6-Ptprj<tm1Taka>. Protein tyrosine phospatase, receptor type J (CD148) is a member of the receptor tyrosine phosphatase family playing an important role in cell growth, differentiation, and development. Homozygous Ptprj<tm1Taka> mutant mice were embryonic lethal due to abnormal cardiovascular system morphology. 国立大学法人東北大学 CD148 KO 条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Mol. Cell. Biol., 23, 1817-1831 (2003).<br>研究成果の公表にあたって謝辞の表明を必要とする。<br>共同研究として用い、寄託後２年間は論文や学会での発表の際は共著とする。寄託者の研究と競合する用途を避けるために、予定の研究概要を寄託者に知らせ、使用許可を得る。本件リソースの特許権ならびに知的所有権は寄託者が保持しており、利用者が本件リソースから得られた結果により特許等を申請する場合には事前に寄託者と別途協議する。 B6.129S6-Ptprj<tm1Taka>/SataRbrc Masanobu SATAKE Cre/loxP system